Routine use of denosumab for prevention of skeletal-related events in patients with bone metastases from prostate carcinoma in Bulgaria: a prospective observational study

References

• International Agency for Research on Cancer. Cancer Fact Sheets: Bulgaria 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/100-bulgaria-fact-sheets.pdf.
   Google Scholar
• Lu J, Hu D, Zhang Y, et al. Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Front Oncol. 2023;13:1. doi: 10.3389/fonc.2023.1133828.
   Web of Science ®Google Scholar
• Ottosson F, Baco E, Lauritzen PM, et al. The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer. Eur Radiol. 2021;31(5):2747–10. doi: 10.1007/s00330-020-07363-x.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223. doi: 10.1056/NEJMoa1213755.
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–1597. doi: 10.1001/jama.281.17.1591.
   PubMed Web of Science ®Google Scholar
• Phillips WJ, Saad F, Leigh J, et al. Real-world evaluation of primary versus secondary prevention of skeletal-related events in metastatic castration-resistant prostate cancer. Oncologist. 2024:oyae036 (Online ahead of print). doi: 10.1093/oncolo/oyae036.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822. doi: 10.1016/S0140-6736(10)62344-6.
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Jensen AØ, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–167. doi: 10.1016/j.juro.2010.03.034.
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–882. doi: 10.1093/jnci/djh141.
   PubMed Web of Science ®Google Scholar
• Coleman R, Hadji P, Body J-J, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650–1663. doi: 10.1016/j.annonc.2020.07.019.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Xgeva(R) (denosumab) – Summary of product characteristics: European Medicines Agency [Internet]. 2022 [updated 2022 July25]. Available from https://www.ema.europa.eu/en/documents/product-information/xgeva-epar-product-information_en.pdf.
   Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082–3092. doi: 10.1016/j.ejca.2012.08.002.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body J-J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–5139. doi: 10.1200/JCO.2010.29.7101.
   PubMed Web of Science ®Google Scholar
• Henry D, Vadhan-Raj S, Hirsh V, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679–687. doi: 10.1007/s00520-013-2022-1.
   PubMed Web of Science ®Google Scholar
• Hegemann M, Bedke J, Stenzl A, et al. Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Ther Adv Urol. 2017;9(3-4):81–88. doi: 10.1177/1756287216686018.
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Basch E, et al. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29(27):3695–3704. doi: 10.1200/JCO.2011.35.8648.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47. doi: 10.1111/j.1524-4733.2007.00213.x.
   PubMed Web of Science ®Google Scholar
• Jacobson D, Cadieux B, Higano CS, et al. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: a real-world machine learning approach. J Bone Oncol. 2022;34:100423. doi: 10.1016/j.jbo.2022.100423.
   PubMed Web of Science ®Google Scholar
• Haslbauer F, Petzer A, Safanda M, et al. Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis. Support Care Cancer. 2020;28(4):1855–1865. doi: 10.1007/s00520-019-04988-7.
   PubMed Web of Science ®Google Scholar
• Diel IJ, Greil R, Janssen J, et al. Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study. Support Care Cancer. 2022;30(11):9267–9278. doi: 10.1007/s00520-022-07333-7.
   PubMed Web of Science ®Google Scholar
• Porubská M, Němcová A. Persistence of denosumab in Slovak patients with bone metastases – a prospective observational study. Klin Onkol. 2023;36(1):54–64. doi: 10.48095/ccko202354.
   PubMedGoogle Scholar
• MD Anderson Cancer Center. The Brief Pain Inventory. 1991. Available from: https://www.mdanderson.org/research/departments-labs-institutes/departments-divisions/symptom-research/symptom-assessment-tools/brief-pain-inventory.html.
   Google Scholar
• Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1–24. doi: 10.1080/08870449908407311.
   Web of Science ®Google Scholar
• Verbrugghe M, Timmers L, Boons CC, et al. Adherence to oral anticancer agents: healthcare providers’ perceptions, beliefs and shared decision making in Belgium and the Netherlands. Acta Oncol. 2016;55(4):437–443. doi: 10.3109/0284186X.2015.1119307.
   PubMed Web of Science ®Google Scholar
• Morote J, Aguilar A, Planas J, et al. Definition of castrate resistant prostate cancer: new insights. Biomedicines. 2022;10(3):689. doi: 10.3390/biomedicines10030689.
   PubMed Web of Science ®Google Scholar
• Hernandez RK, Quigley J, Pirolli M, et al. Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Support Care Cancer. 2014;22(10):2697–2705. doi: 10.1007/s00520-014-2251-y.
   PubMed Web of Science ®Google Scholar
• Qian Y, Bhowmik D, Kachru N, et al. Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States. Support Care Cancer. 2017;25(6):1845–1851. doi: 10.1007/s00520-017-3583-1.
   PubMed Web of Science ®Google Scholar
• Diel I, Ansorge S, Hohmann D, et al. Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany. Support Care Cancer. 2020;28(11):5223–5233. doi: 10.1007/s00520-020-05357-5.
   PubMed Web of Science ®Google Scholar
• AlZahrani M, Clemons M, Vandermeer L, et al. Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: a physician survey. J Bone Oncol. 2021;26:100339. doi: 10.1016/j.jbo.2020.100339.
   PubMed Web of Science ®Google Scholar
• Abousaud AI, Barbee MS, Davis CC, et al. Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study. Ther Adv Med Oncol. 2020;12:1758835920982859. doi: 10.1177/1758835920982859.
   Web of Science ®Google Scholar
• Kettle JK, Patel PB. Feasibility of extended dosing intervals of denosumab. J Oncol Pharm Pract. 2017;24(5):343–347. doi: 10.1177/1078155217703791.
   PubMed Web of Science ®Google Scholar
• Marshall VK, Given BA. Factors associated with medication beliefs in patients with cancer: an integrative review. Oncol Nurs Forum. 2018;45(4):508–526. doi: 10.1188/18.Onf.508-526.
   PubMed Web of Science ®Google Scholar